Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast
Authors:
- 19 August 2015
- journal article
- review article
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 21 (3) , 112-121
Abstract
Traditional menopausal hormone therapy containing estrogens/progestin has been associated with an increased risk of breast cancer, and estrogen exposure is known to promote growth and proliferation of a majority of breast cancers. Therefore, it is important for clinicians to consider the breast safety profile of any hormone-based therapy used in postmenopausal women. This review provides an overview of the breast safety and tolerability profiles of currently marketed selective estrogen receptor modulators, antiestrogens, and the first tissue selective estrogen complex combining conjugated estrogens with the selective estrogen receptor modulator bazedoxifene in postmenopausal women. Selective estrogen receptor modulators and antiestrogens act as estrogen receptor antagonists in the breast. Tamoxifen, toremifene, and the selective estrogen receptor degrader fulvestrant are used to treat breast cancer, and tamoxifen and raloxifene protect against breast cancer in high-risk women. Postmenopausal women using selective estrogen receptor modulators for prevention or treatment of osteoporosis (raloxifene, bazedoxifene) can be reassured that these hormonal treatments do not adversely affect their risk of breast cancer and may, in the case of raloxifene, even be protective. There are limited data on breast cancer in women who use ospemifene for dyspareunia. Conjugated estrogens/bazedoxifene use for up to two years did not increase mammographic breast density or breast pain/tenderness, and there was no evidence of an increased risk of breast cancer, suggesting that conjugated estrogens/bazedoxifene has an improved breast safety profile compared with traditional menopausal hormone therapies. Future research will continue to focus on development of selective estrogen receptor modulators and selective estrogen receptor modulator combinations capable of achieving the ideal balance of estrogen receptor agonist and antagonist effects.Keywords
This publication has 65 references indexed in Scilit:
- Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized TrialsJAMA, 2013
- Four decades of discovery in breast cancer research and treatment an interview with V. Craig JordanThe International Journal of Developmental Biology, 2011
- Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trialOsteoporosis International, 2010
- Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled StudyJournal of Bone and Mineral Research, 2008
- Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patientsBreast Cancer Research, 2007
- Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestinMaturitas, 2006
- Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical PracticeNew England Journal of Medicine, 2003
- First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trialThe Lancet, 2002
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 1998
- Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients With Node-Negative Breast CancerJNCI: Journal of the National Cancer Institute, 1990